Dose clinical dosage of dexamethasone inhibits the effect of sugammadex in reversing rocuronium?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001603

Enrollment

Registered

2015-08-27

Start date

2015-09-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Before induction, Dexa group was given dexamethasone 0.15 mg/kg (maximum 10mg) intravenously, and the same volume of normal saline was given to the Control group.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing laryngeal microscopic surgery or nasal bone reduction operation under general anesthesia American Society of Anesthesiologists (ASA) physical status classification system of I-II Aged 20-60 years

Exclusion criteria

Exclusion criteria: Difficult intubation was anticipated If patients had a neuromuscular disorder that could impair neuromuscular block Significant renal or hepatic dysfunction A (family) history of malignant hyperthermia Allergy to narcotics,neuromuscular blocking agents, or other medication used during general anesthesia Receiving medications expected to interfere with the neuromuscular blocking agents

Design outcomes

Primary

Measure	Time frame
the time from the start of sugammadex administration until recovery of the TOF ratio to 0.9.	—

Secondary

Measure	Time frame
oxygen saturation;respiratory rate	—

Countries

Korea, Republic of

Contacts

Public ContactDuk Hee Chun

Bundang CHA General Hospital

leah1013@chamc.co.kr

Outcome results